

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of active CDK2 [2 – 298] / Cyclin A2 [171 – 432]**

**Enzyme description:-** CDK2 [2 – 298] / Cyclin A2 [171 – 432]

**Clone number:-** CDK2 [2 – 298] DU 1043  
Cyclin A2 [171 – 432] DU 1064

**Source:-** Recombinant

**Expression system:-** *E.coli*

**Tag:-** N-terminal GST for both proteins

**Purification method:-**

Following expression separately, bacterial pellets are mixed prior to lysis, purified by GSH Sepharose chromatography and the GST tags cleaved with PreScission protease. The cleaved proteins are purified by gel filtration chromatography.

**Calculated molecular mass:-**

Monoisotopic 60, 583.62 daltons (CDK2 after cleaving)  
29, 999.50 (Cyclin A after cleaving)  
Average Mass 33, 942.47 daltons (CDK2 after cleaving)  
30, 018.76 (Cyclin A after cleaving)

[cysteines reduced, methionines have not been oxidised]

**Theoretical pI:-** 8.81 CDK2 cleaved and 6.14 Cyclin A cleaved

**Purity:-** 90 %

**Activation protocol:-**

CDK2 / Cyclin A2 (1  $\mu$ M) is activated in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.1 mM sodium vanadate, 10 mM MgAc, 0.1 mM ATP with 1  $\mu$ M active CAK1 [DU 1089] at 30 °C for 30 min. Following activation, the CAK1 is removed from the preparation by GSH Sepharose chromatography.

**Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 50 % glycerol, 150 mM NaCl, 0.1 mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 0.2 mM PMSF, 1 mM Benzamidine.

**Storage temperature:-** -20 °C

**Assay buffer:-**

50 mM Tris-HCl pH 7.5, 0.1 % 2-mercaptoethanol, 0.1 mM EGTA, 0.1 mM sodium vanadate, 10 mM magnesium acetate

## *Division of Signal Transduction Therapy*

**Substrate:-** Histone H1 Final concentration: 1 mg/ml

### **Clone Data Sheet**

#### **CDK2 [2 – 298]**

**Protein** CDK2 [2 – 298]

**Clone number** DU 1043

**Species** Human

**Accession number** NM\_001798

**Tags** N-terminal GST

**Bacterially  
expressed protein**

MSPILGYWKIKGLVQPTRLLEYLEEKYEEHLYERDEGDKWRNKKFEL  
GLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAIEISMLE  
GAVLDIRYGVSRIAYSKDFETLKVDLFLSKLPEMLKMFEDRLCHKTYLN  
GDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKY  
LKSSKYIAWPLQGWQATFGGGDHPKSDLEVLFOGPLGSENFQKVEKI  
**GEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIRESLLKEL**  
**NHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKS**  
**YLFQLLOGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGV**  
**PVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRAL**  
**FPGDSEIDQLFRIFRTLGTPEVVWPGVTSMPDYKPSFPKWARQDFSK**  
**VVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPPFQDVTKPVPHLRL**

**Native sequence** Amino acids E2 – L298 (end) of human CDK2.  
Residue E232 of the fusion protein is equivalent to E2 of the native  
enzyme. The GST tag is located between residues 1- 220.

**Protease cleavage** PreScission (LEVLFQGP) at residues 221 – 229

**Cloning sites** *Bam*H1 and *Eco*R1 site of pGEX6P-1

*Division of Signal Transduction Therapy*

**Nucleotide  
sequence of  
insert**

GGATCCGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTAC  
GGAGTTGTGTACAAAGCCAGAAACAAGTTGACGGGAGAGGTGGTGGCG  
CTTAAGAAAATCCGCCTGGACACTGAGACTGAGGGTGTGCCCAGTACT  
GCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCATCCTAATATT  
GTCAAGCTGCTGGATGTCATTACACAGAAAATAAACTCTACCTGGTT  
TTTGAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCT  
CTCACTGGCATTCTCTTCCCCTCATCAAGAGCTATCTGTTCCAGCTG  
CTCCAGGGCCTAGCTTTCTGCCATTCTCATCGGGTCCTCCACCGAGAC  
CTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCCATCAAGCTA  
GCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTTCGTACTTAC  
ACCCATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTG  
GGCTGCAAATATTATTCCACAGCTGTGGACATCTGGAGCCTGGGCTGC  
ATCTTTGCTGAGATGGTGA CTGCGCCGGCCCTATTCCCTGGAGATTCT  
GAGATTGACCAGCTCTTCCGGATCTTTCGACTCTGGGGACCCAGAT  
GAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGT  
TTCCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTG  
GATGAAGATGGACGGAGCTTGTATCGCAAATGCTGCACTACGACCCT  
ACAAGCGGATTTTCGGCCAAGGCAGCCCTGGCTCACCCCTTCTTCCAG  
GATGTGACCAAGCCAGTACCCCATCTTCGACTctgagaattc

*Division of Signal Transduction Therapy*

**CLONE DATA SHEET**

**Cyclin A2 [171 – 432]**

<b><u>Protein</u></b>	Cyclin A2 [171 - 432]
<b><u>Clone Number</u></b>	DU 1064
<b><u>Species</u></b>	Human
<b><u>Accession number</u></b>	NM_001237
<b><u>Tags</u></b>	N-terminal GST
<b><u>Bacterially expressed protein</u></b>	<p>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFEL GLEFPNLPYYIDGDVKLTSMAIIRYIADKHNMLGGCPKERAETSMLE GAVLDIRYGVSRIAYSKDFETLKVDFLSKLPPEMLKMFEDRLCHKTYLN GDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKY LKSSKYIAWPLQGWQATFGGGDHPKSDLEVLFGQPLGSSVNEVPDYH <b>EDIHTYLREMEVKCKPKVGYMKKQPDITNSMRAILVDWLVEVGEEYKL</b> <b>QNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAAMLLASKFEEIYPPEV</b> <b>AEFVYITDDTYTKQVLRMEHLVVKVLTFDLAAPTVMQFLTQYFLHQQ</b> <b>PANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTQGS</b> <b>WPESLIRKTGYTLESCLKPCLMDLHQTYLKAPQHAQOSIREKYKNSKYH</b> <b>GVSLNPPETLNL</b></p>
<b><u>Native sequence</u></b>	<p>Amino acids S171 – L432 (end) of human Cyclin A2. Residue S232 of the fusion protein is S171 of the native protein. The GST tag is located between residues 1 - 220.</p>
<b><u>Protease cleavage</u></b>	PreScission ( <u>LEVLFQGPL</u> ) at residues 221 – 229
<b><u>Cloning sites</u></b>	<i>Bam</i> H1 and <i>Eco</i> R1 site of pGEX6P-1

*Division of Signal Transduction Therapy*

**Nucleotide  
sequence of  
insert**

GGATCCAGTGTTAATGAAGTACCAGACTACCATGAGGATATTCACACA  
TACCTTAGGGAAATGGAGGTTAAATGTAAACCTAAAGTGGGTTACATG  
AAGAAACAGCCAGACATCACTAACAGTATGAGAGCTATCCTCGTGGAC  
TGGTTAGTTGAAGTAGGAGAAGAATATAAACTACAGAATGAGACCCTG  
CATTTGGCTGTGAACTACATTGATAGGTTCCCTGTCTTCCATGTCAGTG  
CTGAGAGGAAAACCTTCAGCTTGTGGGCACTGCTGCTATGCTGTTAGCC  
TCAAAGTTTGAAGAAATATACCCCCAGAAGTAGCAGAGTTTGTGTAC  
ATTACAGATGATACCTACACCAAGAAACAAGTTCTGAGAATGGAGCAT  
CTAGTTTTGAAAGTCCTTACTTTTGACTTAGCTGCTCCAACAGTAAAT  
CAGTTTCTTACCCAATACTTTCTGCATCAGCAGCCTGCAAACGCAA  
GTTGAAAGTTTAGCAATGTTTTTGGGAGAATTAAGTTTGATAGATGCT  
GACCATACCTCAAGTATTTGCCATCAGTTATTGCTGGAGCTGCCTTT  
CATTTAGCACTCTACACAGTCACGGGACAAAGCTGGCCTGAATCATTA  
ATACGAAAGACTGGATATACCCTGGAAAGTCTTAAGCCTTGTCTCATG  
GACCTTCACCAGACCTACCTCAAAGCACCACAGCATGCACAACAGTCA  
ATAAGAGAAAAGTACAAAATTCAAAGTATCATGGTGTCTCTCCTC  
AACCCACCAGAGACACTAAATCTGtaagaattc